LEADER trial (revision 2)
Old revision·16:19, 12 Sep 2024·PioneerPerdita
This is an old revision of this page, as it stood at 16:19, 12 Sep 2024, saved by PioneerPerdita with the summary British spelling per PP:MOS. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| LEADER trial | |
|---|---|
| Drug | Liraglutide up to 1.8 mg daily |
| Population | Type 2 diabetes, high cardiovascular risk |
| Participants | 9,340 |
| Primary result | MACE HR 0.87 (95% CI 0.78–0.97) |
| Topic infobox · conventions | |
LEADER was a randomised, double-blind, placebo-controlled cardiovascular outcome trial of liraglutide in 9,340 adults with type 2 diabetes at high cardiovascular risk, followed for a median 3.8 years.[1]
The primary composite outcome occurred in 13.0% of the liraglutide group and 14.9% of the placebo group, a hazard ratio of 0.87 (95% CI 0.78–0.97). Cardiovascular death was reduced, and all-cause mortality was lower in the liraglutide group.[1]